Education
About Us
Working with TipRanks
Follow Us
Monte Rosa Therapeutics (GLUE)
NASDAQ:GLUE
Total Valuation
Monte Rosa Therapeutics has a market cap or net worth of $302.63M. The enterprise value is $351.49M.
Market Cap$302.63M
Enterprise Value$351.49M
Share Statistics
Monte Rosa Therapeutics has 61,509,823 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding61,509,823
Owned by Insiders22.89%
Owned by Institutions39.96%
Financial Efficiency
Monte Rosa Therapeutics’s return on equity (ROE) is -0.33 and return on invested capital (ROIC) is -29.45%.
Return on Equity (ROE)-0.33
Return on Assets (ROA)-0.17
Return on Invested Capital (ROIC)-29.45%
Return on Capital Employed (ROCE)-0.29
Revenue Per Employee532.55K
Profits Per Employee-511.97K
Employee Count142
Asset Turnover0.17
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Monte Rosa Therapeutics is -7.06. Monte Rosa Therapeutics’s PEG ratio is -0.08.
PE Ratio-7.06
PS Ratio0.00
PB Ratio1.32
Price to Fair Value2.30
Price to FCF-3.41
Price to Operating Cash Flow-3.89
PEG Ratio-0.08
Income Statement
In the last 12 months, Monte Rosa Therapeutics had revenue of 75.62M and earned -72.70M in profits. Earnings per share was -0.98.
Revenue75.62M
Gross Profit67.50M
Operating Income-81.11M
Pretax Income-70.13M
Net Income-72.70M
EBITDA-72.99M
Earnings Per Share (EPS)-0.98
Cash Flow
In the last 12 months, operating cash flow was 34.67M and capital expenditures -4.19M, giving a free cash flow of 30.48M billion.
Operating Cash Flow34.67M
Free Cash Flow30.48M
Free Cash Flow per Share0.50
Dividends & Yields
Monte Rosa Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.04
52-Week Price Change33.79%
50-Day Moving Average4.43
200-Day Moving Average6.10
Relative Strength Index (RSI)59.39
Average Volume (3m)427.91K
Important Dates
Monte Rosa Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Monte Rosa Therapeutics as a current ratio of 2.40, with Debt / Equity ratio of 17.32%
Current Ratio2.40
Quick Ratio2.40
Debt to Market Cap<0.01
Net Debt to EBITDA2.49
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Monte Rosa Therapeutics has paid 2.57M in taxes.
Income Tax2.57M
Effective Tax Rate-0.04
Enterprise Valuation
Monte Rosa Therapeutics EV to EBITDA ratio is -4.54, with an EV/FCF ratio of 8.72.
EV to Sales4.38
EV to EBITDA-4.54
EV to Free Cash Flow8.72
EV to Operating Cash Flow7.89
Balance Sheet
Monte Rosa Therapeutics has $326.07M in cash and marketable securities with $41.86M in debt, giving a net cash position of -$284.21M billion.
Cash & Marketable Securities$326.07M
Total Debt$41.86M
Net Cash-$284.21M
Net Cash Per Share-$4.62
Tangible Book Value Per Share$3.02
Margins
Gross margin is 0.00%, with operating margin of -107.26%, and net profit margin of -96.14%.
Gross Margin0.00%
Operating Margin-107.26%
Pretax Margin-92.74%
Net Profit Margin-96.14%
EBITDA Margin-96.52%
EBIT Margin-107.26%
Analyst Forecast
The average price target for Monte Rosa Therapeutics is $14.75, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$14.75
Price Target Upside200.41% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast61.09%